Thelansis

  Renal cell carcinoma (RCC) represents the predominant form of kidney cancer, constituting approximately 90% of all renal malignancies. Several factors, including tumor stage at diagnosis, patient age, overall health, and tumor mutation profiles, influence the prognosis of RCC. Refractory or relapsed RCC is observed in 20% to 30% of patients. Although the 5-year overall survival rate for RCC patients is approximately 75%, the median survival for those with refractory or relapsed disease is only 19 to 37 months, underscoring the necessity for efficacious later-line treatments. The management of advanced RCC is particularly challenging and necessitates a comprehensive understanding of the evolving treatment landscape. Various therapeutic agents, including vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, immune checkpoint inhibitors, and mTOR inhibitors, have been approved for treating advanced RCC. Thelansis’s “Relapsed or Refractory Renal Cell C...